Posted 23 June, 2023

ABVC BIOPHARMA, INC. appointed Dr. Uttam Yashwant Patil as new CEO

Nasdaq:ABVC appointed new Chief Executive Officer Dr. Uttam Yashwant Patil in a 8-K filed on 23 June, 2023.

  The Company's board of directors appointed Dr. Uttam Yashwant Patil to replace Dr. Doong as the Company's CEO.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Health Care/Life Sciences • Biotechnology
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
Market Cap
View Company Details
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Dr. Howard Doong, the Chief Executive Officer ("CEO") of ABVC BioPharma, Inc. (the "Company"), notified the Company of his resignation, effective June 21, 2023. Dr. Doong's decision to resign was not the result of any disagreements with the Company on any matter related to the operations, policies, or practices of the Company.

The Company's board of directors appointed Dr. Uttam Yashwant Patil to replace Dr. Doong as the Company's CEO. Dr. Patil has served as the Chief Operating and Scientific Officer of the Company's subsidiary, BioKey, Inc. since May 2023; he also works for Rgene Corporation (a related party), as the R&D Manager since May 2023, after being promoted from Project Manager, to which he serves from August 2022 to May 2023. Prior to that, Dr. Patil was a Post-Doctoral Research Fellow at NTNU from March 2020 to July 2022. In 2019, Dr. Patil received the "Platinum Award" for an Oral Presentation on the topic, "Nucleobase Functionalized Single-Walled Carbon Nanotubes Hybridization with Single-Stranded DNA" at a Workshop on Organic Chemistry for Junior Chemists held in South Korea. Dr. Patil received his Ph.D. in Chemistry from National Tsing Hua University and a Masters in Analytical Chemistry from Pune University, as well as a Bachelors in industrial chemistry from Pune University. 

There are no family relationships between Dr. Patil and any executive officer or director of the Company.